随机试验的荟萃分析：基于吉西他滨的分子靶向治疗对不可切除胰腺癌的疗效评估 - Suppr

Meta-analysis of randomized trials: evaluation of benefit of gemcitabine-based molecular targeted therapy for inoperable pancreatic cancer.

作者信息

Cao Yunfei, Wu Liucheng, Tan Aihua, Liu Lidan, Liao Cun, Gao Feng

出版信息

Pancreas. 2010 Mar;39(2):253-5. doi: 10.1097/MPA.0b013e3181bdc6b8.

DOI:10.1097/MPA.0b013e3181bdc6b8

PMID:20182311

Abstract

摘要

相似文献

Meta-analysis of randomized trials: evaluation of benefit of gemcitabine-based molecular targeted therapy for inoperable pancreatic cancer.

Pancreas. 2010 Mar;39(2):253-5. doi: 10.1097/MPA.0b013e3181bdc6b8.

Gemcitabine doublets in advanced pancreatic cancer: should we move on?

J Clin Oncol. 2006 Jan 20;24(3):327-9. doi: 10.1200/JCO.2005.03.8315. Epub 2005 Dec 12.

[Pancreatic carcinoma: progress in therapy].

Krankenpfl J. 2004;42(5-6):158-9.

Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis.

Pancreatology. 2013 Jul-Aug;13(4):415-22. doi: 10.1016/j.pan.2013.04.195. Epub 2013 Apr 28.

Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.

Acta Oncol. 2017 Mar;56(3):377-383. doi: 10.1080/0284186X.2017.1288922. Epub 2017 Feb 17.

Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.

Hepatobiliary Pancreat Dis Int. 2017 Jun;16(3):236-244. doi: 10.1016/s1499-3872(17)60022-5.

Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).

Oncol Rep. 2010 May;23(5):1183-92. doi: 10.3892/or_00000749.

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

BMC Cancer. 2008 Mar 28;8:82. doi: 10.1186/1471-2407-8-82.

Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer.

J Clin Oncol. 2010 Apr 20;28(12):2058-63. doi: 10.1200/JCO.2009.22.8429. Epub 2009 Aug 17.

Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.

Jpn J Clin Oncol. 2015 Dec;45(12):1122-30. doi: 10.1093/jjco/hyv141. Epub 2015 Oct 30.

引用本文的文献

Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies.

Tumour Biol. 2014 Nov;35(11):11551-8. doi: 10.1007/s13277-014-2451-6. Epub 2014 Aug 17.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Meta-analysis of randomized trials: evaluation of benefit of gemcitabine-based molecular targeted therapy for inoperable pancreatic cancer.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献